AKATINOL MEMANTINE

Active material: Memantine
When ATH: N06DX01
CCF: Glutamatnыh blocking NMDA-receptor. Drug for the treatment of dementia
ICD-10 codes (testimony): F00, F01, G30
Manufacturer: Merz Pharma GmbH & Co. KGaA (Germany)

Pharmaceutical form, composition and packaging

Pills, Film-coated white, oblong, lenticular, scored on each side.

Excipients: lactose, microcrystalline cellulose, colloidal silicon dioxide, talc, magnesium stearate.

The composition of the coating film: methacrylic acid, sodium lauryl, polysorbate 80, triacetine, simethicone emulsion, talc.

10 PC. – blisters (3) – packs cardboard.
10 PC. – blisters (9) – packs cardboard.

Pharmacological action

Preparation, improves brain metabolism, used for the treatment of dementia. Memantine yavlyaetsya nekonkurentnыm antagonistom N-methyl-D-aspartate retseptorov, It has a modulating effect on glutamatergic system. It regulates ion transport, blocking calcium channels, normalises the membrane potential, improves the transmission of nerve impulses. The drug improves cognitive processes, memory and learning ability, increases daily activities.

Pharmacokinetics

Absorption and distribution

After oral administration, memantine is rapidly and completely absorbed from the gastrointestinal tract. C_max It reached within 2-6 no.

In normal renal function, accumulation of memantine is not marked.

Deduction

Withdrawal dwuhfazno. T_1/2 averages in the first phase 4-9 no, in the second phase – 40-65 no. Excreted in the urine.

Testimony

- Type dementia alytsgeymerovskogo;

- Sosudistaya dementia;

- Mixed dementia of all severities.

Dosage regimen

The drug is taken orally with meals. The mode set individually. Start of treatment is recommended to assign the minimum effective dose.

Adults at dementia syndrome prescribe the drug for the 1st week of treatment at a dose of 5 mg / day, within 2 weeks – at a dose of 10 mg / day, within 3 weeks – by 15-20 mg / day. If necessary, may further increase weekly dose 10 mg to achieve a daily dose of 30 mg.

The optimal dose is achieved gradually, with increasing doses every week.

Side effect

The incidence of adverse reactions is classified as follows: Often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10 000, <1/1000), rarely (<1/10 000), frequency is not installed (current data on the prevalence of adverse reactions are absent).

CNS: often – headache, drowsiness, dizziness; rarely – confusion, hallucinations (mainly, in patients with Alzheimer's disease at a stage severe dementia), gait disturbance; rarely – convulsions; frequency is not installed – psychotic reactions (There are some reports of the occurrence of adverse events when using the drug in clinical practice / data, received after the appearance of the drug in the sale /).

From the digestive system: often – constipation; rarely – nausea, vomiting; frequency is not installed – pancreatitis.

Cardio-vascular system: rarely – arterial hypertension, venoznыy thrombosis, thromboembolism.

Other: rarely – fatiguability.

Contraindications

- Expressed by the human kidney;

- Lactation (breast-feeding);

- Pregnancy;

- Up to 18 years (insufficient data);

- Hypersensitivity to the drug.

FROM caution prescribers in thyrotoxicosis, epilepsy, convulsions (incl. history), myocardial infarction, Heart Failure.

Pregnancy and lactation

Akatinol Memantine is contraindicated during pregnancy and lactation (breast-feeding).

Cautions

Effects on ability to drive vehicles and management mechanisms

In patients with Alzheimer's disease at a stage of moderate or severe dementia usually impair the ability to drive vehicles and management of complex mechanisms. Besides, memantine causes a change in the reaction rate, so patients, receiving outpatient treatment, Be particularly careful when driving or operating machinery.

Overdose

Symptoms: possibly increasing incidence described side effects.

Treatment: gastric lavage, administration of activated charcoal; if necessary, symptomatic therapy.

Drug Interactions

In an application with akatinol Memantine drug L-dopa, agonistami dopamina, anticholinergics may be enhanced effects last.

In an application with barbiturates akatinol Memantine, neuroleptic action of the latter may be reduced.

When combined memantine may change (enhance or reduce) effect of dantrolene or Batrafen, so the doses of drugs should be selected individually.

Avoid co-administration with amantadine, ketaminom and dekstrometorfanom.

In a joint application with memantine may increase levels of cimetidine, prokaynamyda, xinidina, quinine and nicotine.

In a joint application with memantine may reduce the level of hydrochlorothiazide.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children at or above 25 ° C. Shelf life – 4 year.